DePuy-Synthes eliminates all non-sales travel in a bold cost-cutting measure

DEPUY SYNTHES CONTINUES COST-CUTTING (Orthopedics This week)
DePuy Synthes continues its cost-cutting measures.
According to a July 17, 2014, Wall Street Journal Pharmalot blog, the company is eliminating all travel for the rest of the year. The sales force is exempt.
It was also reported that all consulting contracts valued at more than $50,000 must now obtain top-level approval.
The Journal obtained an internal memo written by Pete Batesko III, the unit’s vice president of finance and CFO. The memo reportedly stated that, “Despite our progress in so many areas, DePuy Synthes faces short-term...